Home » STRESSGEN BIOTECHNOLOGIES ANNOUNCES THIRD QUARTER 2005 FINANCIAL RESULTS
STRESSGEN BIOTECHNOLOGIES ANNOUNCES THIRD QUARTER 2005 FINANCIAL RESULTS
Stressgen Biotechnologies ("The Company") (TSX: SSB) announced today
financial results for the third quarter ended September 30, 2005. All amounts,
unless specified otherwise, are in Canadian dollars. Stressgen reported a net
loss from continuing operations of $5.7 million, or $0.08 (US$0.07) per share,
for the three months ended September 30, 2005, compared to a net loss from continuing
operations of $8.4 million, or $0.12 (US$0.09) per share, for the same period
in 2004.
PR
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May